http://rdf.ncbi.nlm.nih.gov/pubchem/patent/AR-050253-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_07b71571160c289fbf5fc680dfea513f |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-445 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D401-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P13-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D409-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D413-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P19-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P19-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P19-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D401-04 |
| filingDate | 2005-06-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2006-10-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | AR-050253-A1 |
| titleOfInvention | COMPOSITE DERIVED FROM INDAZOL CARBOXAMIDE, COMPOSITION THAT INCLUDES IT AND ITS USE FOR THE PREPARATION OF A MEDICINAL PRODUCT |
| abstract | Compound derived from indazole carboxamide having the formula (1) in which Z is optionally substituted aryl or optionally substituted heteroaryl, said aryl and heteroaryl being optionally substituted with one or more substituents selected, independently, from the group consisting of: halo, optionally substituted C1-6 alkyl, optionally substituted C1-6 haloalkyl, optionally substituted heterocycloalkyl, CN, N (Rb) SO2Re, N (Rb) C (O) Ra, C (O) NRaRb, C (O) NRaRb, C ( O) NRxRy, SO2NRaRb, SO2NRxRy, ORc, N (Rb) C (O) NRaRb, N (Rb) C (0) NRxRy, N (Rb) C (O) ORd, said C1-6 alkyl and haloalkyl C1- being said 6 optionally substituted with one or more substituents selected from the group consisting of: NRaRb, C3-6 cycloalkyl, ORc, phenyl and heterocycloalkyl optionally substituted with one or two C1-6 alkyl groups; R1 is H, halo, or -WX; W is a C1-6 alkylene or bond; X is optionally substituted aryl, optionally substituted heteroaryl, optionally substituted heterocycloalkyl, optionally substituted C4-7 cycloalkyl, optionally substituted C5-7 cycloalkenyl, N (Rb) SO2Re, N (Rb) C (O) Re, N (Rb) C ( O) ORd, N (Rb) C (O) NRaRb, or N (Rb) C (o) NRxRy, said aryl, heteroaryl, heterocycloalkyl, C4-7 cycloalkyl, and C5-7 cycloalkenyl being optionally substituted with one or more substituents independently selected from the group consisting of: halo, optionally substituted C1-6 alkyl, optionally substituted C1-6 haloalkyl, ORc, C (O) Rg, C (O) ORf, N (Rb) SO2Re, N (Rb) C (O) Ra, C (O) NRaRb, SO2NRaRb, SO2Re, and heterocycloalkyl, said C1-6 alkyl and C1-6 haloalkyl being optionally substituted with a phenyl group; each Ra is independently selected from the group consisting of H, optionally substituted alkyl, C1-3, optionally substituted phenyl, optionally substituted heteroaryl, optionally substituted C3-7 cycloalkyl, and optionally substituted heterocycloalkyl, said C1-3 alkyl being optionally substituted with one or more substituents selected from the group consisting of: halo, ORc, C1-6 haloalkyl, phenyl and heteroaryl; and said phenyl, heteroaryl, C3-7 cycloalkyl, and heterocycloalkyl optionally being substituted with one or more substituents selected from the group consisting of: halo, ORc, C1-6 alkyl, and C1-6 haloalkyl each Rb is selected, in an independent manner, of the group consists of: H and optionally substituted C1-3 alkyl, said C1-3 alkyl being optionally substituted with one or more ORc groups; each Rc is independently selected from the group consisting of: H, optionally substituted C1-6 alkyl, optionally substituted C3-7 cycloalkyl, optionally substituted heterocycloalkyl, and optionally substituted aryl, and optionally substituted aryl, optionally substituted heteroaryl, said being C1-6 alkyl and C1-6 haloalkyl optionally substituted with one or more substituents selected from the group consisting of: C3-6 cycloalkyl, phenyl, heterocycloalkyl, and heteroaryl; and said aryl and heteroaryl being optionally substituted with one or more substituents selected from the group consisting of: halo, C1-3 alkyl, C1-3 haloalkyl and OH; and said C3-7 cycloalkyl and heterocycloalkyl being optionally substituted with one or more C1-3 alkyl groups; Rd side is optionally independently substituted C1-3 alkyl, said C1-3 alkyl being optionally substituted with one or more substituents selected from the group consisting of: C3-6 cycloalkyl, phenyl optionally substituted with one or more substituents selected from the group consisting of : halo, C1-6 alkyl, and C3-6 cycloalkyl; and heteroaryl optionally substituted with one or more substituents selected from the group consisting of: halo, C 1-6 alkyl, and C 3-6 cycloalkyl; each Re is independently selected from the group consisting of: optionally substituted C1-6 alkyl, optionally substituted phenyl, optionally substituted heteroaryl, optionally substituted C5-7 cycloalkyl, and optionally substituted heterocycloalkyl, said C1-6 alkyl being optionally substituted with a substituent selected from the group consisting of: ORc, trifluoromethyl, phenyl, heteroaryl, heterocycloalkyl optionally substituted with ORc or with heterocycloalkyl, NRaRb; said phenyl and heteroaryl being optionally substituted with one or more substituents selected from the group consisting of: halo, CN, C1-6 alkyl, N (Rb) C (O) Ra, and ORh; and said C5-7 cycloalkyl and heterocycloalkyl being optionally substituted with one or more substituents selected from the group consisting of: halo, C1-6 alkyl optionally substituted with ORc, and C3-6 cycloalkyl, each Rf is independently selected from the group consisting of H and optionally substituted C1-4 alkyl, said C1-4 alkyl may be optionally substituted with one or more substituents selected from the group consisting of: C3-6 cycloalkyl; phenyl optionally substituted with one or more substituents selected from the group consisting of: halo, C1-6 alkyl, and heteroaryl optionally substituted with one or more substituents selected from the group consisting of: halo, C1-6 alkyl, and C3-6 cycloalkyl; each Rg is independently selected from the group consisting of: optionally substituted C1-3 alkyl, optionally substituted phenyl, optionally substituted heteroaryl, optionally substituted C3-7 cycloalkyl and optionally substituted heterocycloalkyl, said C1-3 alkyl being optionally substituted with one or more substituents selected from the group consisting of: halo and C1-6 haloalkyl; and said phenyl, heteroaryl, C3-7 cycloalkyl, and heterocycloalkyl optionally being substituted with one or more phenyl, heteroaryl, C3-7 cycloalkyl, and heterocycloalkyl optionally substituted with one or more substituents selected from the group consisting of: Halo, C1-6 alkyl , and C1-6 halolakyl, each Rh is independently selected from the group consisting of: H, C1-6 alkyl, and C1-6 haloalkyl; and Rx and Ry, taken together with the nitrogen atom to which they are attached, form a ring having 5 to 7 member atoms, said ring optionally containing an additional heteroatom as a member atom being said ring being saturated or unsaturated, but not aromatic, and said ring being optionally substituted with one or two C1-3 alkyl substituents; or one of its pharmaceutically acceptable salts. Composition comprising it and its use for the preparation of a medicament for treating disorders in which an inappropriate activity of IKK2 (also called IKKbeta) is involved, such as rheumatoid arthritis, asthma and chronic obstructive pulmonary disease (COPD) COPD), inflammatory disorders, Alzheimer's disease, AIDS, heart attack, cancer or cachexia. |
| priorityDate | 2004-06-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 48.